Scpie Holdings Inc

Scpie — Merger or Acquisition (December 2007)

19 slides from Scpie's merger presentation, Dec 5, 2007

  1. Slide 1: Schedule 14A

    Slide 1: Schedule 14A

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy

  2. Slide 2: SCPIE's Proposed Transaction with The Doctors Company: Maximizing Shareholder Value

    Slide 2: SCPIE's Proposed Transaction with The Doctors Company: Maximizing Shareholder Value

    SCPIE’s Proposed Transaction with The Doctors Company: Maximizing Shareholder Value December 2007

  3. Slide 3: Safe Harbor Statement

    Slide 3: Safe Harbor Statement

    Safe Harbor Statement In addition to historical information, this presentation contains forward-looking statements that are based upon SCPIE’s estimates and expectations concerning future events and are subject to certain risks and uncertainties that could cause actual results to differ materially f

  4. Slide 4: Summary

    Slide 4: Summary

    Summary SCPIE conducted a thorough evaluation of strategic alternatives Comprehensive auction process The time to sell is now Scrupulous adherence to corporate governance tenets The Doctors Company bid is the most direct path to shareholder value maximization 3

  5. Slide 5: Historical process snapshot

    Slide 5: Historical process snapshot

    Historical process snapshot August 2006 – Strategic Planning Committee established to identify and analyze current and future business prospects January 2007 – Deutsche Bank hired to provide financial advisory and investment banking services March 2007 – Board reached the decision to pursue a sale i

  6. Slide 6: SCPIE's Board observes prevailing corporate governance practices

    Slide 6: SCPIE's Board observes prevailing corporate governance practices

    SCPIE’s Board observes prevailing corporate governance practices Majority of Board is independent Strategic Planning Committee established Investment banker retained Independent Directors retain independent counsel in connection with the auction process Potential conflict identified: Board member Jo

  7. Slide 7: Outlook for stand-alone SCPIE supports a sale today

    Slide 7: Outlook for stand-alone SCPIE supports a sale today

    Outlook for stand-alone SCPIE supports a sale today Outlook for stand-alone growth/profitability For the nine months ended September 30, 2007 (year to date), net written premiums of $95.6 million as compared to $98.9 during the same period one year ago California (one core state) medical malpractice

  8. Slide 8: SCPIE's share price has continued to underperform

    Slide 8: SCPIE's share price has continued to underperform

    SCPIE’s share price has continued to underperform Med mal 1-year YTD 1-year 1-year indexed indexed price price ended ended October October 15, 15, 2007 2007 Company growth growth ACAP 22.5% 3.9% 120 FPIC 16.1 14.9 PRA 10.0 8.1 115 Average 16.2% 9.0% SKP (21.5)% (15.5)% 110 105 P&C 100 1-year YTD Com

  9. Slide 9: The med mal market is dominated by large, highly-rated companies

    Slide 9: The med mal market is dominated by large, highly-rated companies

    The med mal market is dominated by large, highly- rated companies: SCPIE’s rating loss and relative size compromises its competitiveness 1998 2003 2006 Med mal net A.M. Med mal net A.M. Med mal net A.M. premiums Best premiums Best premiums Best Company name written rating Company name written rating

  10. Slide 10: Over the last five years, SCPIE has traded at an average of 49% discount to peers

    Slide 10: Over the last five years, SCPIE has traded at an average of 49% discount to peers

    Over the last five years, SCPIE has traded at an average of 49% discount to peers on a price to book basis Since 2003, the med mal industry has recovered from record low book value multiples SCPIE continues to trade at a discount to its peers No foreseeable change in A.M. Best rating before 2010 5-y

  11. Slide 11: SCPIE faces significant financial challenges

    Slide 11: SCPIE faces significant financial challenges

    SCPIE faces significant financial challenges Net premium growth is constrained SCPIE has maximized its net income given its net premiums To improve ratings (and allow for more growth) SCPIE is accumulating capital (equity/ surplus) With stagnant net income and rising equity, ROAE will be challenged

  12. Slide 12: SCPIE has lowest ROAE among its peers

    Slide 12: SCPIE has lowest ROAE among its peers

    SCPIE has lowest ROAE among its peers ROAE is driven by growth in earnings and/or capital management PRA has generated growth through acquisitions,and ACAP and FPIC have managed capital primarily through share repurchases to maintain ROAE and EPS growth Neither of these options is available to SCPIE

  13. Slide 13: SCPIE book value multiple is unlikely to improve

    Slide 13: SCPIE book value multiple is unlikely to improve

    SCPIE book value multiple is unlikely to improve Achieving higher return on equity (ROAE) is typically rewarded with higher price/book trading multiples SCPIE pre announcement was trading relatively in line with the broader market; without improvement in its ROAE, it seems unlikely that its book val

  14. Slide 14: SCPIE Board ran a robust auction

    Slide 14: SCPIE Board ran a robust auction

    SCPIE Board ran a robust auction March 2007 - October 2007 25 potential strategic and financial buyers contacted 11 signed confidentiality agreements Reverse due diligence explored on 3 stock bidders; 1 proceeded to advanced stages 4 active final bidders The Doctors Company final bid represents a 9.

  15. Slide 15: SCPIE Holdings Inc. to be acquired by The Doctors Company

    Slide 15: SCPIE Holdings Inc. to be acquired by The Doctors Company

    SCPIE Holdings Inc. to be acquired by The Doctors Company On October 16, 2007, SCPIE Holdings Inc. (NYSE: The transaction SKP) announced that it had entered into a definitive Value agreement to be acquired by The Doctors Company, $28.00/share ($/share) a leading physician-owned medical malpractice c

  16. Slide 16: The Doctors Company bid is the most direct path to shareholder value maximization

    Slide 16: The Doctors Company bid is the most direct path to shareholder value maximization

    The Doctors Company bid is the most direct path to shareholder value maximization Form of Consideration The Doctors Company (TDC) offer Illustrative offer from peer stock company Declining acquiror share price can negatively impact the value of the consideration payable, e.g., due to Fixed cash amou

  17. Slide 17: The Doctors Company bid is in line with transaction comparables

    Slide 17: The Doctors Company bid is in line with transaction comparables

    The Doctors Company bid is in line with transaction comparables Precedent Precedent transactions transactions analysis analysis GAAP Statutory Announce date Buyer Target Deal value Price / book Price / surplus 10/05/2006 Doctors Co OHIC Insurance Co $85.0 NA 1.04x 12/08/2005 ProAssurance Phys Insura

  18. Slide 18: Conclusion

    Slide 18: Conclusion

    Conclusion Board conducted a thorough auction process that included strategic and financial prospective buyers The Doctors Company’s all cash $28 per share bid is the most direct path to maximizing shareholder value Fixed valuation Certainty of closing – No shareholder approval required by The Docto

  19. Slide 19: Additional information and where to find it

    Slide 19: Additional information and where to find it

    Additional information and where to find it SCPIE intends to file a definitive proxy statement in connection with the proposed acquisition.The proxy statement will be mailed to SCPIE’s stockholders, who are urged to read the proxy statement and other relevant materials when they become available bec

Source: SEC EDGAR · DEFA14A filed Dec 5, 2007

More decks from Scpie Holdings Inc